Transactions of Managers and Closely Associated Persons

Alvotech (ALVO) disclosed filings to the Luxembourg CSSF showing a single share transfer within the Aztiq group: 2,701,617 shares were sold and acquired on January 30, 2026 at USD 4.74 per share.

Rhea-AI Summary

Alvotech (ALVO) disclosed filings to the Luxembourg CSSF showing a single share transfer within the Aztiq group: 2,701,617 shares were sold and acquired on January 30, 2026 at USD 4.74 per share. The notices reflect an intra‑group transfer between ATP Holdings ehf. and Aztiq Pharma Partners S.à r.l.

Contact provided: Benedikt Stefansson, VP investor relations, valvotech.ir@alvotech.com.

Argus Feb 27 session

-4.09% close to close Open Argus

Details

News Market Reaction – ALVO

On Feb 27, the first trading day after this news, ALVO closed 4.09% below the previous close.

Data tracked by StockTitan Argus for the Feb 27 session.

Market Context

This announcement details an internal transfer of 2,701,617 shares at USD 4.74 per share between ent...

Analysis

This announcement details an internal transfer of 2,701,617 shares at USD 4.74 per share between entities within the Aztiq group, highlighting continued transparency around transactions by managers and closely associated persons. Because the shares moved within the same ownership group, the economic impact on outside shareholders appears limited. Investors following Alvotech may focus more on prior news about capital increases, clinical milestones, and commercialization agreements when assessing the overall equity story.

Key Figures

Shares transferred: 2,701,617 shares Transaction price: USD 4.74 per share Current share price: USD 4.09

Shares transferred

2,701,617 shares

Intra-group transfer on January 30, 2026

Transaction price

USD 4.74 per share

Price for 2,701,617-share intra-group transaction

Current share price

USD 4.09

Pre-news market price from context data

Historical Context

5 past events · Latest: Feb 11

5 events

1. Feb 11

   Share capital increase

   24h Move

   -6.7%

   Issued 12,500,000 new shares to subsidiary to support prior obligations.

2. Feb 05

   Clinical trial results

   24h Move

   -2.0%

   Pivotal PK study for AVT80 met all primary endpoints versus Entyvio.

3. Feb 02

   Commercial agreements

   24h Move

   -0.9%

   Signed Sandoz supply and commercialization deals for multiple biosimilars.

4. Jan 29

   Settlement agreement

   24h Move

   +2.5%

   Global licensing and settlement for Eylea biosimilar enabling staged launches.

5. Jan 07

   Insider transaction correction

   24h Move

   +1.5%

   Corrected CSSF filings for large insider-related share trades in Dec 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. announced a sale of 2,701,617 shares in Alvotech on January 30, 2026, and Aztiq Pharma Partners S.à r.l. ("Aztiq") announced the acquisition of 2,701,617 shares in Alvotech on January 30, 2026. ATP Holdings ehf. belongs to the Aztiq group and the transaction was thus a transfer of shares within the group. The announcements related to the same transaction and the transaction price was USD 4.74 per share.

ALVOTECH INVESTOR RELATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com

Attachments

• Notification - Aztiq Pharma Partners 2026-02-26
• ATP Managers' Transaction Notification 2026-02-11

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did ALVO disclose on February 26, 2026?

It disclosed a registered intra‑group transfer of 2,701,617 shares on January 30, 2026. According to the company, ATP Holdings ehf. sold and Aztiq Pharma Partners acquired the shares at USD 4.74 per share and both filings were filed with the CSSF.

Does the ALVO filing show a market sale or intra‑group transfer?

The filing shows an intra‑group transfer rather than an arms‑length market sale. According to the company, ATP Holdings belongs to the Aztiq group and the transaction represented a transfer of shares within that group on January 30, 2026.

How many ALVO shares changed hands and at what price on January 30, 2026?

A total of 2,701,617 shares were reported transferred at USD 4.74 per share. According to the company, both the sale and the acquisition were notified to the Luxembourg CSSF as related parts of the same transaction.

Which parties were involved in the ALVO managers' transaction notices?

The notices named ATP Holdings ehf. and Aztiq Pharma Partners S.à r.l. as the selling and acquiring parties. According to the company, ATP Holdings belongs to the Aztiq group, making the move an intra‑group transfer reported to the CSSF.

Where can investors direct inquiries about the ALVO transaction disclosure?

Investors can contact Benedikt Stefansson, VP investor relations, using the provided email address. According to the company, investor relations contact is valvotech.ir@alvotech.com for questions about the CSSF notifications dated February 26, 2026.